DOSSIER · UPDATED 18 NOV 2025

ARCELLX

Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. The Company's proprietary ARC-sparX platform separates the…

arcellx.com ↗Claim this profile
Founded
2020
Headcount
109
Open roles
0
Last raised
Post Ipo Equity · $200M
SECTION I · THE BRIEF

Inside ARCELLX

Brief #54298Updated 18 NOV 2025GAITHERSBURGMEDICAL ORGANIZATIONSPOST IPO EQUITY
Employbl Dossier

ARCELLX

Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. The Company's proprietary ARC-sparX…

Founded
2020
Headcount
109
Open roles
0
Last raised
Post Ipo Equity · $200M
Section II — RestrictedMembers only
  • Tech stack (ARCELLX engineering primaries)
  • Hiring focus this quarter
  • Interview format & rubric
  • Comp bands by level
  • Decision-makers in talent
  • Recent news & moves
Open ARCELLX briefSign in

7-day free trial · $25/mo · cancel anytime

TAGS

Categorized in

Company Collections

These are collections ARCELLX is a part of. Click on the collection name to view similar companies.

ARCELLX's Industries

ARCELLX's Tech Stack

LOCATIONS

Where they work

ARCELLX Headquarters Location

Gaithersburg, MD, 20899

Loading map…
FUNDING

Capital raised

Total Amount Raised: $622,000,000

ARCELLX Funding Rounds

  • Post Ipo Equity

    $200,000,000

  • Post Ipo Equity

    $200,000,000

    Post Ipo Equity Investors

    Kite Pharma

  • Post Ipo Equity

    $100,000,000

  • Post Ipo Equity

    $100,000,000

    Post Ipo Equity Investors

    Kite Pharma

  • Post Ipo Equity

    $112,000,000

  • Post Ipo Equity

    $112,000,000

  • Post Ipo Equity

    $9,999,986

  • Post Ipo Equity

    $9,999,986

  • IPO

    Unknown

  • Series C

    $115,000,000

  • Series C

    $115,000,000

    Series C Investors

    CAM Capital
    Samsara BioCapital
    Cambrian
    Asymmetry Ventures
    Adage Capital Management
    CaaS Capital Management
    Sixty Degree Capital
    Surveyor Capital
    Soleus Capital
    Terra Magnum Capital Partners
    Suvretta Capital Management
    Sr One
    NEA - New Enterprise Associates
    Takeda Ventures
    Clough Capital Partners
    Novo Holdings
    LG Technology Ventures

  • Series B

    $85,000,000

  • Series B

    $85,000,000

    Series B Investors

    AJU IB Investment Co
    Quan Capital
    Mirae Asset Venture Investment Co.
    Clough Capital Partners
    Sr One
    Mirae Asset Capital
    Takeda Ventures
    Novo Holdings
    NEA - New Enterprise Associates
    JVC Investment Partners
    LG Technology Ventures
    Solasta Ventures
Funding info provided by Diffbot.
EMPLOYEE REVIEWS

On the ground at ARCELLX

ARCELLX Reviews

0 out of 5 stars

Based on 0 reviews

Review data

Share your thoughts

Worked here? Share your experience. Help others decide if this company is right for them. Write a review on ARCELLX.

Recent reviews